Precision Biosciences Stock Price, News & Analysis

On November 2, 2022, Precision BioSciences (DTIL) announced the approval of inducement awards for 15 new employees, comprising stock options for 272,352 shares at an exercise price of $1.39. The options are part of the 2021 Employment Inducement Incentive Award Plan, and will vest over four years. Precision BioSciences focuses on developing ARCUS-based gene editing therapies, aimed at treating genetic and infectious diseases.

Precision BioSciences (Nasdaq: DTIL) announced an accepted abstract for poster presentation at the 64th American Society of Hematology Annual Meeting in New Orleans from December 10-13, 2022. The poster will detail the effective cell dose and functional attributes of its lead CD19 candidate, Azercabtagene Zapreleucel (azer-cel), in treating relapsed or refractory non-Hodgkin lymphoma. This analysis highlights the product's composition and cell doses, which may improve safety and efficacy. Dr. Alan List emphasized the significance of maximizing naïve cell phenotype in allogeneic CAR T therapy.

Precision BioSciences, Inc. (Nasdaq: DTIL) has announced plans to publish its financial results for the third quarter of 2022 on November 8, 2022, along with a business update. The company focuses on developing ex vivo allogeneic CAR T and in vivo gene editing therapies using its proprietary ARCUS® genome editing platform. This platform is designed for therapeutic safety and versatility and aims to address genetic and infectious diseases lacking effective treatments.

Precision BioSciences (Nasdaq: DTIL) announced an inducement grant for Michael Amoroso, its CEO, under the 2021 Employment Inducement Incentive Award Plan. This grant includes an option to purchase 250,000 shares at a price of $1.38, with 25% vesting on October 15, 2023, and the remainder vesting over three years. The grant complies with Nasdaq Listing Rules as material to Mr. Amoroso's employment. Precision BioSciences specializes in gene editing therapies using its proprietary ARCUS® platform, targeting genetic and infectious diseases.

Precision BioSciences, Inc. (NASDAQ: DTIL) announced its participation in the Jefferies Cell & Genetic Medicine Summit on September 30, 2022, at 2:00 PM ET, located at the Lotte New York Palace Hotel. A recorded webcast will be available on the company’s website shortly after the presentation, with an archived replay accessible for 30 days. The company focuses on developing innovative gene editing therapies using its proprietary ARCUS® platform, targeting genetic and infectious diseases lacking effective treatments. For further details, visit www.precisionbiosciences.com.

Precision BioSciences, Inc. (NASDAQ: DTIL) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. A fireside chat is scheduled for September 13, 2022, at 4:30 PM ET, located at the Lotte New York Palace Hotel. The session will be available via a recording on Precision's website the next day, with an archived replay for 30 days. Precision BioSciences focuses on gene editing using its ARCUS® platform to develop CAR T and gene editing therapies for genetic and infectious diseases.

Precision BioSciences (NASDAQ: DTIL) announced organizational changes, promoting Cindy Atwell to Chief Business Officer, Jeff Smith to Chief Research Officer, and Derek Jantz to focus on company strategy as Chief Scientific Officer. These changes aim to enhance leadership and align responsibilities in advancing the company's ARCUS-based ex vivo CAR T and in vivo gene editing therapies. CEO Michael Amoroso expressed confidence in the leadership team’s commitment to patients and the company’s growth towards becoming a commercial stage entity.

Precision BioSciences, Inc. (DTIL) announced key developments in its second quarter 2022 update. The company launched a collaboration with Novartis for an in vivo gene insertion treatment targeting hemoglobinopathies. They reported a cash balance of approximately $184.1 million, extending their financial runway through 2024. Interim results from the PBCAR0191 CAR T study showed a 100% overall response rate among relapsed subjects. However, total revenues fell to $3.8 million, down $65 million year-over-year, primarily due to the absence of previous revenues from the Servier Agreement.